About Robert Weisskoff
Robert Weisskoff is a senior partner at F-Prime Capital and an Adela director; he joined F-Prime in 2004. Its portfolio includes life sciences, technology, health technology and services. He has spent 30 years in academia and bioscience. Earlier, he held senior research and business development roles at drug and medical-device companies. He was an associate professor of radiology at Harvard Medical School and taught in the Harvard-MIT Health Sciences Technology program. At Massachusetts General Hospital, he conducted research and was associate director of the MGH-NMR Center. He has written more than 100 peer-reviewed papers and is named on six U.S. patents. He earned degrees from MIT, Columbia University and Harvard University.
He serves on six other company boards, including Affinia Therapeutics, RareCyte and Zenflow. His prior board work includes Caribou Biosciences, Farapulse and ViewRay. He also joined Tempest Therapeutics' board during its Series B financing.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Robert Weisskoff in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Robert Weisskoff works with at each company, as listed on that company's latest Form D.
